Clinical trial
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in…
NCT00268671 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00268671 |
|---|---|
| Title | Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN) |
| Official title | Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel |
| Enrollment | 45 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Dec 22, 2005 |
| Last update posted | Dec 7, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: